Sign in4 stories
The clinical-stage biotech said Subramanian took over as principal financial officer on September 9, 2026, while Macleod stays on through October to help with the transition.
SEC filing
The company also disclosed a binding MENA licensing term sheet for OCU400 and said cash runway now extends into 2028.
SEC filing
Roots Pharmaceutical and partner Al-Dhow International Holding gain exclusive rights to Ocugen's retinitis pigmentosa gene therapy across the Middle East and North Africa under a binding term sheet.
SEC filing